Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 4 Carcinoma, Renal Cell 3 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Castration-resistant Prostate Cancer 2 Urologic Neoplasms 1 Stomach Neoplasms 1 Osteosarcoma 1 Lymphatic Metastasis 1 Ependymoma 1 Colonic Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Breast Neoplasms 1 Bone Neoplasms 1 Adenocarcinoma 1

Interventions

Methotrexate 21 Ifosfamide 21 Cyclophosphamide 19 Doxorubicin 17 Cisplatin 14 Filgrastim 13 Gemcitabine 12 Etoposide 11 Leucovorin 9 apatinib 8 fludarabine 7 glucarpidase 6 Vincristine 6 Temozolomide 6 Radiotherapy 6 Nivolumab 6 Neoadjuvant Therapy 6 Drug Therapy 6 Carboplatin 6 regorafenib 5 cabozantinib 5 Zoledronic Acid 5 Topotecan 5 Mesna 5 Irinotecan 5 Granulocyte Colony-Stimulating Factor 5 Docetaxel 5 pembrolizumab 4 pegfilgrastim 4 camrelizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Osteosarcoma × Metastasectomy × Clear all

NCT06114225 2023-11-02

PROMIS

Ruijin Hospital

Phase 2 Recruiting

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡